Loading…
Loading…
Fujifilm Holdings is a diversified Japanese conglomerate spanning four segments: Imaging (Instax instant cameras/film, digital cameras, photo paper/printing), Healthcare (X-ray and MRI/ultrasound imaging systems via the former Hitachi Healthcare business, endoscopes, in-vitro diagnostics, and Fujifilm Diosynth's biologics contract manufacturing), Electronics Materials (semiconductor process chemicals — CMP slurries, photoresists, cleaning chemistries — sold to chipmakers rather than chips made in-house), and Business Innovation (formerly Fuji Xerox document/office equipment).
Widely held, no controlling shareholder — top holders are trust-bank nominee accounts (custodians for underlying institutional/retail beneficial owners). Foreign institutions hold ~45% of shares in aggregate (BlackRock ~6.9%, Nomura Asset Management ~6.1%, Vanguard ~4.3% per third-party aggregation, not independently confirmed against the company's own top-10 table this tick). GLEIF reports no parent entity on file. Fujifilm Holdings Corporation is itself the top of the group (parent of FUJIFILM Corporation, Fujifilm Diosynth Biotechnologies, etc.) — not a subsidiary of anything, so no parent_slug applies.
Named counterparties identified by open-source research and written only where a primary source states the relationship — never inferred from sector or co-mention. 1 customer-side. This is a partial view: it covers the relationships we could evidence, not the company's full supply base.
FUJIFILM Diosynth Biotechnologies (Fujifilm's biologics CDMO unit) signed a 10-year U.S. manufacturing supply agreement with Regeneron valued at over \$3 billion, using capacity at Fujifilm's Holly Springs, NC facility. This is a contract-manufacturing relationship, not a critical-material flow — none of the dossier's material_exposures (silver, tin, tantalum, tungsten) are implicated. No revenue-share percentage disclosed.
Scope. Absence of a counterparty here is not evidence that none exists — most commercial sourcing is confidential and never becomes public. Rows without a share figure mean no share was disclosed, not that the relationship is small.
Every exposure is read as a buyer dependency; the top 3 are its binding chokepoints.
As a buyer, policy pressure across its consumed materials is rising.
Descriptive trend in official policy actions on this company’s materials — a policy-pressure trend, not a price or trading signal. No forward probability is implied. Direction is measured on actions we have discovered, and discovery lags events: where the recent window is too thin to support a calm reading, the row says coverage-limited instead of easing.
No actions in the register have named or swept this company in the last 24 months.